Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis

Table 1 Clinical characteristics of responders and non-responders at baseline

	Responders	Non-responders	p value
Number of patients	27	8
Age, year	59.4 ± 13.1	67.4 ± 12.5	N.S.
Female, n (%)	22 (81.5)	5 (62.5)	N.S.
Disease duration, month	109.2 ± 147.9	50.25 ± 56.7	N.S.
RF titer, mg/dl	69.7 ± 78.3(n = 26)	83.5 ± 74.3	N.S.
RF positivity, n (%)	20 (76.9)	8 (100)	N.S.
Anti-CCP antibody titer, U/ml	92.8 ± 94.0(n = 25)	120.7 ± 117	N.S.
Anti-CCP antibody positivity, n (%)	25 (91.6)	8 (100)	N.S.
DAS28-CRP	4.37 ± 1.04	3.81 ± 0.98	N.S.
Use of PSL, n (%)	5 (18.5)	3 (37.5)	N.S.
PSL dose, mg/day	6.4 ± 5.0	10.25 ± 7.2	N.S.
Use of MTX, n (%)	19 (70.0)	2 (25.0)	0.04
MTX dose, mg/week	10.61 ± 3.7	9.0 ± 4.2	N.S.

Values are expressed as the mean ± SD. Fisher’s exact test and Student’s t test were used to compare categorical and continuous variables between the two groups, respectively. p < 0.05 was considered statistically significant
N.S. not significant, RF rheumatoid factor, CCP cyclic citrullinated peptide, DAS28-CRP disease activity score in 28 joints using C-reactive protein, PSL prednisolone, MTX methotrexate

ISSN: 1478-6362